A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.
复制标题

DOI:
10.1038/nm.3806
复制
发表时间:
2015-03
期刊:
影响因子:
82.9
通讯作者:
O'Neill, Luke A. J.
O'Neill, Luke A. J.
中科院分区:
医学1区
文献类型:
--
作者:
Coll, Rebecca C.;Robertson, Avril A. B.;Chae, Jae Jin;Higgins, Sarah C.;Munoz-Planillo, Raul;Inserra, Marco C.;Vetter, Irina;Dungan, Lara S.;Monks, Brian G.;Stutz, Andrea;Croker, Daniel E.;Butler, Mark S.;Haneklaus, Moritz;Sutton, Caroline E.;Nunez, Gabriel;Latz, Eicke;Kastner, Daniel L.;Mills, Kingston H. G.;Masters, Seth L.;Schroder, Kate;Cooper, Matthew A.;O'Neill, Luke A. J.

文献摘要

参考文献

被引文献

相似文献

NLRP3炎症小体是炎症过程的一个组成部分,其异常激活在遗传性疾病(如crypyrin相关周期性综合征(CAPS))和复杂疾病(如多发性硬化症、2型糖尿病和动脉粥样硬化)中具有致病性。我们描述了MCC950的发展,MCC950是一种有效的,选择性的NLRP3小分子抑制剂。MCC950在纳摩尔浓度下阻断典型和非典型NLRP3的激活。MCC950特异性抑制NLRP3,但不抑制AIM2、NLRC4或NLRP1的激活。MCC950降低体内白细胞介素-1p (IL-1β)的产生,减轻实验性自身免疫性脑脊髓炎(EAE)的严重程度,EAE是多发性硬化症的一种疾病模型。此外,MCC950治疗在CAPS小鼠模型中挽救了新生儿死亡率,并且在mucle - wells综合征个体的离体样本中具有活性。因此,MCC950是NLRP3相关综合征(包括自身炎症和自身免疫性疾病)的潜在治疗药物,也是进一步研究NLRP3炎性体在人类健康和疾病中的作用的工具。
The NLRP3 inflammasome is a component of the inflammatory process and its aberrant activation is pathogenic in inherited disorders such as the cryopyrin associated periodic syndromes (CAPS) and complex diseases such as multiple sclerosis, type 2 diabetes and atherosclerosis. We describe the development of MCC950, a potent, selective, small molecule inhibitor of NLRP3. MCC950 blocks canonical and non-canonical NLRP3 activation at nanomolar concentrations. MCC950 specifically inhibits NLRP3 but not AIM2, NLRC4 or NLRP1 activation. MCC950 reduces Interleukin-1p (IL-1β) production in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis. Furthermore, MCC950 treatment rescues neonatal lethality in a mouse model of CAPS and is active in ex vivo samples from individuals with Muckle-Wells syndrome. MCC950 is thus a potential therapeutic for NLRP3-associated syndromes, including autoinflammatory and autoimmune diseases, and a tool for the further study of the NLRP3 inflammasome in human health and disease.
DOI: 10.1038/ni.1702
发表时间: 2009-03-01
期刊: NATURE IMMUNOLOGY
影响因子: 30.5
作者:
Buerckstuemmer, Tilmann;Baumann, Christoph;Superti-Furga, Giulio
通讯作者: Superti-Furga, Giulio
DOI: 10.1038/ni.1631
发表时间: 2008-08
期刊: Nature immunology
影响因子: 30.5
作者:
通讯作者: --
DOI: 10.4049/jimmunol.1202737
发表时间: 2013-01-01
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者:
He Y;Franchi L;Núñez G
通讯作者: Núñez G
DOI: 10.1016/j.smim.2013.10.008
发表时间: 2013-12-15
影响因子: 7.8
作者:
Dinarello CA;van der Meer JW
通讯作者: van der Meer JW
DOI: 10.1073/pnas.1111101108
发表时间: 2011-09-06
影响因子: 11.1
作者:
Jin, Chengcheng;Frayssinet, Patrick;Flavell, Richard A.
通讯作者: Flavell, Richard A.